Company DescriptionKissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality. The company's products in pipeline include KPS-0373 that has completed Phase III clinical trial to treat spinocerebellar ataxia; CCX168, which has completed Phase III clinical trial for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; R788 that is in Phase III clinical trial to treat chronic idiopathic thrombocytopenic purpura; and MR13A9, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. It is also developing KLH-2109 for treating endometriosis and uterine fibroids; KDT-3594 for the treatment of Parkinson's disease; Silodosin for dysuria associated with benign prostatic hyperplasia; Mitiglinide for type 2 diabetes mellitus; and Bedoradrine for the treatment of acute exacerbation of asthma. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, equipment and facility management, and information gathering and development support services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was founded in 1946 and is headquartered in Matsumoto, Japan.

How the Company Makes Money

Kissei Pharmaceutical Co Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Breakdown
Income Statement		Total Revenue
83.39B	75.58B	67.49B	65.38B	69.04B	63.24B
	Gross Profit
41.89B	37.34B	32.38B	31.24B	32.72B	34.91B
	EBIT
4.09B	4.02B	-1.13B	-1.40B	1.50B	1.86B
	EBITDA
17.46B	18.72B	17.81B	20.26B	10.65B	7.21B
	Net Income Common Stockholders
11.66B	11.16B	10.53B	12.92B	5.29B	2.82B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
48.74B	45.93B	49.60B	53.15B	44.45B	59.67B
	Total Assets
147.02B	260.93B	221.20B	238.09B	268.86B	231.79B
	Total Debt
3.51B	1.34B	1.49B	1.64B	1.74B	1.76B
	Net Debt
-19.14B	-21.55B	-24.40B	-28.37B	-18.71B	-34.57B
	Total Liabilities
22.80B	39.80B	26.39B	35.91B	48.91B	38.83B
	Stockholders Equity
124.04B	220.03B	193.90B	201.38B	219.31B	192.46B
Cash Flow		Free Cash Flow
0.00	-3.51B	-9.23B	-386.00M	-4.03B	12.63B
	Operating Cash Flow
0.00	-1.68B	-6.68B	1.53B	-2.54B	13.93B
	Investing Cash Flow
0.00	8.69B	6.00B	10.78B	-9.33B	490.00M
	Financing Cash Flow
0.00	-10.01B	-3.42B	-2.76B	-4.00B	-4.42B

Kissei Pharmaceutical Co Peers Comparison

Overall Rating

UnderperformOutperform

Sector (54)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KSPHF		$1.22B	15.08	5.47%	2.44%	―	―
Sector *	54 Neutral	$5.31B	3.28	-45.10%	2.80%	16.76%	0.02%
KKPCF		$943.41M	11.14	9.44%	4.73%	―	―
TRXPF		$1.23B	28.25	4.56%	2.13%	―	―
TWAPF		$1.06B	10.01	11.38%	1.83%	―	―
MFY		€611.94M	17.96	4.35%	2.80%	―	―
4887	69 Neutral	¥174.66B	9.49		3.02%	-3.69%	76.69%

* Healthcare Sector Average

Performance Comparison

KSPHF

Kissei Pharmaceutical Co

27.13

6.99

34.71%

KKPCF

Kaken Pharmaceutical Co

26.44

2.71

11.42%

TRXPF

Torii Pharmaceutical Co

36.62

13.56

58.80%

TWAPF

Towa Pharmaceutical Co

25.33

7.41

41.35%

DE:MFY

Mochida Pharmaceutical Co., Ltd.

17.60

0.02

0.11%

JP:4887

SAWAI GROUP HOLDINGS Co., Ltd.

1,780.00

-107.89

-5.71%

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.